(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
25 September 2025 (25.09.2025)

WIPO | PCT

(10) International Publication Number
WO 2025/196590 A1

(51) International Patent Classification:
C12N 15/62 (2006.01) *C12N 15/85* (2006.01)
A61K 40/31 (2025.01) *C12N 5/10* (2006.01)
C07K 16/30 (2006.01) *A61P 35/00* (2006.01)

(21) International Application Number:
PCT/IB2025/052672

(22) International Filing Date:
13 March 2025 (13.03.2025)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
202421019457 16 March 2024 (16.03.2024) IN

(71) Applicants: **INDIAN INSTITUTE OF TECHNOLOGY BOMBAY** [IN/IN]; Powai, Maharashtra, Mumbai 400076 (IN). **IMMUNOADOPTIVE CELL THERAPY PRIVATE LIMITED** [IN/IN]; First Floor, Plot R-977, TTC Industrial Area, MIDC Rabale, Maharashtra, Navi Mumbai 400701 (IN).

(72) Inventors: **PURWAR, Rahul Kailash**; 1515 Chittranjan Tower, Maharashtra, Mumbai 400076 (IN). **KHAN, Aalia Nizamuddin**; 103 Apna Ghar CHS, Mahada, Malavani, Malad West, Maharashtra, Mumbai 400095 (IN). **KARULKAR, Atharva Ajay**; A/602, Borgoankar Tower CHS, Agra Road, Lal Chowki, Kalyan West, Maharashtra, Thane 421301 (IN).

(74) Agent: **MAJUMDAR, Subhatosh** et al.; S. Majumdar & Co., 5, Harish Mukherjee Road, West Bengal, Kolkata 700 025 (IN).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *with amended claims (Art. 19(1))*
— *with sequence listing part of description (Rule 5.2(a))*

(54) Title: NOVEL ANTI-BCMA CHIMERIC ANTIGEN RECEPTOR, ITS NUCLEIC ACID SEQUENCE, AND ITS PREPARATION

(57) Abstract: The present invention relates to novel chimeric antigen receptor polypeptide (CAR), wherein the CAR comprises an extracellular antigen-binding domain, comprising an antibody or antibody fragment thereof that binds to a B-cell Maturation Antigen (BCMA) polypeptide. The invention also relates to a nucleic acid molecule encoding the CAR of the invention, a genetically modified immune cell, expressing the CAR of the invention and the use of said cell in the treatment of various medical disorders.

WO 2025/196590 A1